Citigroup analyst Keith Horowitz maintains Fifth Third Bancorp (NASDAQ:FITB) with a Neutral and raises the price target from $37 to $40.
Sage Therapeutics Q2 EPS $(2.13) Beats $(2.15) Estimate, Sales $1.50M Miss $1.76M Estimate
Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.13) per share which beat the analyst consensus estimate of $(2.15) by 0.93 percent. This is a 16.39 percent decrease over losses of $(1.83) per share from
